Trial Site Detail

 

Drug:
Rogaratinib
Trial:
Testing the Anti-cancer Drug, Rogaratinib (BAY 1163877), for Treatment of Advanced Sarcoma With Alteration in Fibroblast Growth Factor Receptor (FGFR 1-4), and in Patients With SDH-deficient Gastrointestinal Stromal Tumor (GIST)
Conditions: Sarcoma
Trial Status:
Completed

 

Ohio State University Comprehensive Cancer Center

     
Columbus , OH 43210
USA

 

Principal Investigator:
Gabriel R. Tinoco Suarez
Contact:
Contact: Site Public Contact 800-293-5066 Jamesline@osumc.edu
Activation Status of this Site:
Active
Notes about this Site:
Ohio State University Comprehensive Cancer Center Website:

 

 

Navigating the Map

Use the plus (+) and minus (-) controls to zoom in/out.

Click and drag the map or use the arrows to move (pan) the map.

Tip: Click the marker before zooming and the map will stay centered on the marker as you zoom.